# Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.

> **NCT00783406** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 20 (estimated)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** PF-00610355
- **DRUG:** PF-00610355
- **DRUG:** PF-00610355
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00783406
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2010-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783406, "Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00783406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*